A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients
NCT06010342 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60
Last updated 2026-04-28
Summary
The main objective of the study will be to evaluate the efficacy of TL118 in participants with solid tumors harboring NTRK gene fusions
Conditions
Interventions
- DRUG
-
TL118 Capsule
Oral administration
Sponsors & Collaborators
-
Teligene US
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-16
- Primary Completion
- 2027-12-31
- Completion
- 2028-12-31
- FDA Drug
- Yes
Countries
- United States
- China
Study Locations
More Related Trials
-
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors
NCT04996121 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
TT-00973-MS Tablets in Patients With Advanced Solid Tumors
NCT05673538 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Phase II Trial of TIL Following CCRT in Patients With Locoregionally Advanced NPC
NCT02421640 ·Status: UNKNOWN ·Phase: PHASE2
-
Clinical Study of HMPL-653 in Treatment of Advanced Malignant Solid Tumors and TGCT
NCT05277454 ·Status: UNKNOWN ·Phase: PHASE1
-
A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma
NCT06781112 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
GP-induced Chemotherapy Combined With IMRT and TPF-induced Chemotherapy Combined With IMRT in the Treatment of Distant Metastatic Nasopharyngeal Carcinoma
NCT03723343 ·Status: UNKNOWN
-
L-TIL in Patients With Malignancy Resistance to Anti-PD-1 Therapy
NCT04268108 ·Status: UNKNOWN
-
Induction Chemotherapy Followed By Chrono-chemotherapy Concurrent With IMRT Of Locally Advanced NPC Clinical Study
NCT02187315 ·Status: UNKNOWN ·Phase: PHASE2
-
Neoadjuvant Therapy of GP Chemotherapy Combined With Tislelizumab in Locoregionally Advanced NPC
NCT04833257 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors
NCT01610479 ·Status: COMPLETED ·Phase: PHASE1
-
Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma
NCT05211232 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)
NCT05798546 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors
NCT05740215 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
A Phase I Study of Hemay181 in Patients With Advanced Solid Tumors
NCT05749432 ·Status: RECRUITING ·Phase: PHASE1
-
NGR-TNF in Treating Patients With Advanced Solid Tumors
NCT00098943 ·Status: COMPLETED ·Phase: PHASE1
-
Single Arm Phase I Trail of Autologous Tumor Infiltrating Lymphocyte Injection (GT202) in the Treatment of Metastatic or Recurrent Gynecological Tumors
NCT05238818 ·Status: UNKNOWN ·Phase: PHASE1
-
To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors
NCT05014828 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of NK510 to Treat NSCLC
NCT06097962 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC
NCT05343325 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
NCT06038396 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma
NCT05342792 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).
NCT05346952 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of FCN-011 in Patients With Advanced Solid Tumor（Phase I）and NTRK Fusion Positive Advanced Solid Tumor （Phase II）
NCT04687423 ·Status: UNKNOWN ·Phase: PHASE1
-
Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer
NCT06554028 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2